KCAS Bio describes itself as "a full-service bioanalytical and biomarker contract research organization (CRO) that helps pharmaceutical and biotech sponsors move drug candidates from discovery through clinical development."[S1] Its headquarters laboratory is in Olathe, Kansas, in the greater Kansas City area.[S4] The reviewed pages describe bioanalytical and biomarker services. No in-life animal study service was found on those pages; that is not a finding that none exists; in a nonclinical program it supports the toxicology or pharmacology CRO that generates the samples. No founding year was found on the pages reviewed, stating only that it has worked with sponsors "for more than 45 years."[S1] This profile summarizes the services, sites, stated compliance information, and company facts most relevant to US sponsors.
Services relevant to US drug developers
Small and large molecule bioanalysis
For small molecules the company states that it "provides GLP/GCP-compliant small molecule bioanalysis, using advanced LC-MS/MS platforms to quantify drugs, metabolites, and biomarkers from discovery through clinical stages."[S8] For large molecules it describes ligand-binding assay work covering proteins, antibodies, antibody-drug conjugates, oligonucleotides and vaccines, stating that it has "over 60 full-time LBA scientists, and over 20 years of experience."[S9] Platforms named across the site include LC-MS/MS, hybrid LC-MS/MS, ligand binding assays, flow cytometry, qPCR and digital PCR, and NULISA.[S1] A news item states that the company "supports studies in a wide range of preclinical species, including mouse, rat, rabbit, dog, minipig, and non-human primates (marmoset and cynomolgus monkey)"[S15] ? the reviewed page does not state whether the animals are housed by the company or elsewhere.
Immunogenicity, biomarkers, and flow cytometry
The company states that it "provides GLP and non-GLP immunogenicity testing and analytical services to detect and characterize humoral and cellular immune responses, including ADAs, NAbs, and antigen-specific activity."[S10] Biomarker work covers soluble and cellular biomarkers across neurology, oncology, immunology and inflammation, infectious disease and metabolic areas, with the company stating that it takes "a scientifically driven approach grounded in the context-of-use of each biomarker."[S13] Flow cytometry is presented as a particular focus: the company describes itself as "a global leader in GLP/GCP-compliant and non-GLP flow cytometry outsourcing"[S11] and states that it is "the only bioanalytical laboratory with globally harmonized Cytek spectral flow cytometers, with sites in the US, EU and Australia."[S1] That last claim is the company's own and is reproduced here as such.
Cell and gene therapy and molecular services
For CAR-T and other cell and gene therapy programs the company states that it "delivers integrated molecular, cellular, and biomarker testing to evaluate safety, potency, persistence, and immune response throughout clinical programs,"[S12] including vector copy number analysis and T-cell phenotyping.[S12] Molecular services use ddPCR and qPCR for biodistribution and pharmacodynamic endpoints,[S13] and the services overview also lists PK and PD bioanalysis, dose formulation analysis with certificates of analysis, central laboratory and sample kitting, and vaccine development support.[S13]
Quality and compliance (as stated by the company)
GLP and related systems. The quality page names the regulations directly: "we adhere to FDA GLP (21 CFR Part 58) and FDA Electronic Records and Signatures (21 CFR Part 11) across applicable projects,"[S2] and "our operations also comply with OECD Principles of GLP (ENV/MC/CHEM(98)17), supporting Mutual Acceptance of Data in OECD-member countries."[S2] The company names FDA 21 CFR Part 58, OECD Principles of GLP in its GLP statement.[S2] GLP compliance is determined study by study under the applicable regulation, so sponsors should confirm in the protocol which regulation their study will follow and that the final report will carry the study director's compliance statement and the quality assurance unit's statement.[R2] The page also cites Good Clinical Laboratory Practice guidance from EMA, WHO and the Research Quality Association for clinical trial sample work, which is a separate framework from GLP.[S2] The Lyon laboratory holds ISO 9001:2015 certification, described as maintained for more than 15 years;[S6] no ISO certification is stated for the US laboratories, and no CLIA statement was found on the pages reviewed.
Inspections and licenses. The company states that it "has had over 20 FDA inspections in our company history"[S2] and lists a Kansas State Board of Pharmacy analytical laboratory certificate, DHHS permits to import infectious biological agents, a DEA controlled substance registration, a US Fish and Wildlife Service import and export license, the Lyon GLP certificate and the Lyon ISO 9001 certificate.[S2] FDA inspects laboratories under its Bioresearch Monitoring program but does not approve or certify them, so an inspection history is not an endorsement.[R6] No AAALAC, USDA or OLAW statement was found on the pages reviewed; that is an absence in those pages, not a finding about the status of the company.
Company facts
Name
KCAS Bio; the French entity is named KCAS Bio ? SAS[S16]
Headquarters
10830 S. Clay Blair Blvd., Olathe, KS 66061, United States (the site describes the location as being in the greater Kansas City metropolitan area)[S4]
Founded
Not stated; the company says it has worked with sponsors for more than 45 years[S1]
Ownership
The company states that it is backed by Vitruvian Partners[S14]
Total headcount not published; the company cites 65 PhDs on staff and over 60 full-time large molecule bioanalysis scientists[S1][S9]
Laboratories
Olathe KS (70,000 sq ft); Lower Gwynedd Township PA (26,000 sq ft); Lyon, France (10,700 sq ft). Melbourne, Australia is a partner laboratory operated by Crux Biolabs under a strategic alliance, not a KCAS Bio site[S4][S5][S6][S7]
Service scope
Bioanalysis, immunogenicity, biomarkers, flow cytometry, molecular assays, cell and gene therapy support. No in vivo studies, toxicology dosing or pathology services are described[S13]
GLP regulations named
FDA 21 CFR Part 58; FDA 21 CFR Part 11; OECD Principles of GLP ENV/MC/CHEM(98)17[S2]
FDA ? "Is It Really FDA Approved?" (FDA does not approve health care providers, including laboratories; registration does not denote approval); FDA Compliance Program 7348.808 (GLP inspections of nonclinical laboratories). https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved (accessed 2026-09-03)
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.
Pharmacology (Efficacy) Studies Replicate unknown pathological models and Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
SMC Laboratories, Inc. has established a disease models using patented mouse technologies.
The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project.
Their collaborative approach allows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc. (Labcorp Drug Development)
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements.
All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials.
For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
PhoenixBio Co., Ltd. offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to–drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides a seamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offers an integrated evaluation analysis covering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics.
For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.
Japanese
